{
    "clinical_study": {
        "@rank": "104377", 
        "arm_group": [
            {
                "arm_group_label": "Group 1", 
                "arm_group_type": "Active Comparator", 
                "description": "aTIV"
            }, 
            {
                "arm_group_label": "Group 2", 
                "arm_group_type": "Experimental", 
                "description": "aTIV + 1X MF59"
            }, 
            {
                "arm_group_label": "Group 3", 
                "arm_group_type": "Experimental", 
                "description": "aTIV + TIV"
            }, 
            {
                "arm_group_label": "Group 4", 
                "arm_group_type": "Experimental", 
                "description": "aTIV + aTIV"
            }, 
            {
                "arm_group_label": "Group 5", 
                "arm_group_type": "Active Comparator", 
                "description": "aTIV (Left deltoid) Saline (Right deltoid)"
            }, 
            {
                "arm_group_label": "Group 6", 
                "arm_group_type": "Experimental", 
                "description": "aTIV+2X MF59 (Left deltoid) Saline (Right deltoid)"
            }, 
            {
                "arm_group_label": "Group 7", 
                "arm_group_type": "Experimental", 
                "description": "aTIV (Left deltoid) aTIV (Right deltoid)"
            }
        ], 
        "brief_summary": {
            "textblock": "In this study, the safety and immunogenicity of the current formulation of aTIV will be\n      compared to aTIV-modified formulations in which the dosage of the MF59 adjuvant will be\n      doubled or tripled and/or the dosage of the 3 influenza virus strains will be doubled, in\n      independently-living elderly subjects \u2265 65 years of age."
        }, 
        "brief_title": "Safety and Immunogenicity of Different Formulations of an Adjuvanted, Trivalent Subunit Influenza Vaccine in Elderly Subjects 65 Years of Age and Above", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Influenza", 
        "condition_browse": {
            "mesh_term": "Influenza, Human"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male and female subjects \u226565 years of age on the day of screening who are  healthy or\n             have chronic illnesses that are stable and well controlled.\n\n          2. Subjects assessed as mentally competent, who have given informed consent  after the\n             nature of the study has been explained according to local requirements\n\n          3. In good health as determined by:\n\n               1. Ability to live independently\n\n               2. Medical history\n\n               3. Physical examination\n\n               4. Clinical judgment of the Investigator\n\n          4. Able to understand and comply with all study procedures and visits, and are able to\n             complete an eDiary\n\n          5. Individuals who have access to a working telephone and are able to receive periodic\n             telephone calls\n\n        Exclusion Criteria:\n\n          1. Individuals who have received any type of influenza vaccine (licensed or\n             experimental) within the past 6 months\n\n          2. Individuals who have received any other licensed vaccines within 30 days (for\n             inactivated vaccines) or 42 days (for live vaccines) prior to enrollment in this\n             study\n\n          3. Individuals who have cancer except for:\n\n               1. Benign localized skin cancer\n\n               2. Localized prostate cancer that has been clinically stable for \u2265 2 years without\n                  treatment\n\n               3. Cancer in remission for \u2265 10 years (from end of cancer treatment)\n\n          4. Individuals with autoimmune disease (including rheumatoid arthritis)\n\n          5. Individuals with diabetes mellitus, type I\n\n          6. Individuals with a body mass index (BMI) \u226418 or \u226535.\n\n          7. Asthma that is greater than mild in severity and / or has exacerbations more than 2\n             days per week\n\n          8. Congestive heart failure with symptoms as severe as or more severe than dyspnea with\n             short walks or climbing a single flight of stairs (for example, greater than New York\n             Heart Association class 2)\n\n          9. History of progressive or severe neurologic disorders including but not limited to\n             multiple sclerosis, Parkinson's disease, Guillain-Barr\u00e9 syndrome, amyotrophic lateral\n             sclerosis, Creutzfeldt-Jakob disease, epilepsy disorders requiring medication for\n             control, encephalitis, Alzheimer's and CVA\n\n         10. Individuals who are hypersensitive to ovalbumin, chicken protein, chicken feathers,\n             influenza viral protein, kanamycin and neomycin sulfate or any other component of the\n             vaccines in study\n\n         11. Individuals who have a history of neurological symptoms or signs, or anaphylactic\n             shock following administration of any vaccine\n\n         12. Individuals who have a known or suspected (or have a high risk of developing)\n             impairment/alteration of immune function resulting from, for example,\n\n             a. Receipt of immunosuppressive therapy (defined as follows) within the past 60 days\n             and/or anticipated to receive immunosuppressive therapy at any point within 21 days\n             of Visit 1.\n\n             i. Cancer chemotherapy/radiotherapy ii. Systemic corticosteroids ( i.e., 15 mg or\n             greater per day of prednisone or   equivalent) iii. Chronic use of inhaled/intranasal\n             high potency corticosteroids (budesonide 800 \u03bcg per day or fluticasone 750 \u03bcg per\n             day) b. Receipt of immunostimulants c. Receipt of parenteral immunoglobulin\n             preparation, blood products and/or plasma derivate within the past 3 months and for\n             the full length of the study d. Suspected or known HIV infection or HIV-related\n             disease\n\n         13. Individuals who have a known or suspected history of drug or alcohol abuse\n\n         14. Individuals who, within the past 12 months, have had laboratory confirmed influenza\n             disease\n\n         15. Individuals who, within the past 30 days have received any investigational agent.\n\n         16. Individuals who plan to receive another vaccine within 30 days of receipt of the\n             study vaccination.\n\n         17. Individuals who, within the past 14 days, have experienced:\n\n               1. Any acute disease including any worsening of underlying respiratory diseases\n                  such as asthma or COPD\n\n               2. Infections requiring systemic antibiotic or antiviral therapy (chronic\n                  antibiotic therapy for urinary tract prophylaxis is acceptable)\n\n         18. Individuals who are taking part in another clinical study\n\n         19. Individuals who are research staff directly involved with the clinical study or\n             family members or household members of research staff. Research staff includes an\n             individual with direct or indirect contact with study subjects, or study site\n             personnel who have access to any study documents containing subject information. This\n             would include receptionists, persons scheduling appointments or making screening\n             calls, regulatory specialists, laboratory technicians, etc.\n\n         20. Individuals with behavioral or cognitive impairment or a psychiatric condition that,\n             in the opinion of the investigator, may interfere with the subject's ability to\n             participate in the study.\n\n         21. Vulnerable subjects, e.g. subjects kept in detention, soldiers, employees of the\n             sponsor or a clinical research organization involved in this study\n\n         22. Individuals who have any condition which, in the opinion of the investigator, might\n             interfere with the evaluation of the study objectives."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "65 Years"
        }, 
        "enrollment": {
            "#text": "196", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02126761", 
            "org_study_id": "V133_01 EXP", 
            "secondary_id": "2013-005344-29"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Group 1", 
                    "Group 5"
                ], 
                "description": "Group 1 and group 5 are active comparators; group 5 includes placebo comparator as a second injection in contralateral deltoid", 
                "intervention_name": "Adjuvanted, trivalent subunit influenza vaccine", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "Group 2", 
                    "Group 6"
                ], 
                "description": "Group 2 and group 6 are experimental; group 2 has double dosage of MF59 in a single injection; group 6 has triple dosage of MF59 and includes placebo comparator in contralateral deltoid", 
                "intervention_name": "Adjuvant level modified adjuvanted, trivalent subunit influenza vaccine", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Group 3", 
                "description": "Group 3 is experimental with double the usual antigen dosage", 
                "intervention_name": "Antigen level modified adjuvanted, trivalent subunit influenza vaccine", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "Group 4", 
                    "Group 7"
                ], 
                "description": "Group 4 and 7 are experimental; group 4 has one injection with double the antigen and adjuvant; group 7 has two injections with double the antigen and adjuvant", 
                "intervention_name": "Antigen and adjuvant level modified adjuvanted, trivalent subunit influenza vaccine", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Influenza", 
            "elderly", 
            "adjuvant"
        ], 
        "lastchanged_date": "April 28, 2014", 
        "location": {
            "contact": {
                "email": "Thomas.Koernicke@parexel.com"
            }, 
            "facility": {
                "address": {
                    "city": "Berlin", 
                    "country": "Germany", 
                    "zip": "14050"
                }, 
                "name": "PAREXEL Early Phase Clinical Unit"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "7", 
        "official_title": "A Phase 1, Randomized, Observer Blind, Antigen and Adjuvant Dosage-Finding Study to Evaluate the Safety and Immunogenicity of an Adjuvanted, Trivalent Subunit Influenza Vaccine in Elderly Subjects \u226565 Years of Age", 
        "overall_contact": {
            "last_name": "Novartis Drug Information Services", 
            "phone": "+1 800 244 7668"
        }, 
        "overall_official": {
            "affiliation": "Novartis Vaccines", 
            "last_name": "Novartis Vaccines", 
            "role": "Study Chair"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Germany: Paul-Ehrlich-Institut", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Safety of aTIV or aTIV-modified formulations", 
                "measure": "Reactogenicity up to 7 days after vaccination", 
                "safety_issue": "Yes", 
                "time_frame": "Days 1-7 post-vaccination"
            }, 
            {
                "measure": "Unsolicited AEs within 28 days after vaccination", 
                "safety_issue": "Yes", 
                "time_frame": "Days 1-28 post-vaccination"
            }, 
            {
                "measure": "SAEs, non-scheduled physician visits, unsolicited medically attended AEs, unsolicited AEs leading to study withdrawal, NOCDs, and AESIs from study start to study completion.", 
                "safety_issue": "Yes", 
                "time_frame": "Days 1-366 post-vaccination"
            }, 
            {
                "description": "Antibody responses to all three influenza virus vaccine strains, 21days after a dose or doses of aTIV or aTIV-modified formulations, as measured by hemagglutination inhibition (HI) assay and microneutralization (MN) assay.", 
                "measure": "Seroconversion/significant increase in antibody HI titers; \u22654-fold rise in MN titer 21 days post-vaccination.", 
                "safety_issue": "No", 
                "time_frame": "Day 22 post-vaccination"
            }, 
            {
                "measure": "HI and MN GMT and GMR at baseline and 21 days post-vaccination.", 
                "safety_issue": "No", 
                "time_frame": "Day 1; Day 22 post-vaccination"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02126761"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Seroconversion/significant increase in antibody HI titers; \u22654-fold rise in MN titer, 7 days and 6 months post-vaccination.", 
                "safety_issue": "No", 
                "time_frame": "Day 8 and 181 post-vaccination"
            }, 
            {
                "description": "To compare HI and MN responses to a aTIV or aTIV-modified formulations, at 7 days and 6 months post-vaccination.", 
                "measure": "HI and MN (GMT) 7 days and 6 months post-vaccination.", 
                "safety_issue": "No", 
                "time_frame": "Day 8 and 181 post-vaccination"
            }, 
            {
                "measure": "HI and MN (GMR) 7 days, 21 days, and 6 months post-vaccination.", 
                "safety_issue": "No", 
                "time_frame": "Day 1, 8, 22, and 181 post-vaccination"
            }, 
            {
                "description": "To compare antibody responses in subjects receiving aTIV-modified formulations in a single intramuscular injection (in one deltoid) to two intramuscular injections (one in each deltoid) at 7 days, 21 days, and 6 months post-vaccination.", 
                "measure": "Percentage of subjects with HI titers \u22651:40, \u22651:110, \u22651:160, and \u22651:330 7 days, 21 days, and 6 months post-vaccination.", 
                "safety_issue": "No", 
                "time_frame": "Day 8, 22, and 181 post-vaccination"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "collaborator": {
                "agency": "Novartis Vaccines", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Novartis", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}